Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
(St. Jude Children's Research Hospital) Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St. Jude Children's Research Hospital showcase the power and potential of combining genomic and transcriptomic data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news
Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 7, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Epidemiology of Visceral Mycoses in Patients with Acute Leukemia and Myelodysplastic Syndrome: Analyzing the National Autopsy Database in Japan
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 7, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
$5M grant to help Wash U research blood disorder therapies
The Washington University School of Medicine has received a $5 million grant from the Edward P. Evans Foundation to create a new center that will research rare blood disorders.
The center will focus on a specific set of disorders, called myelodysplastic syndromes (MDS), which prohibits the body from creating enough healthy blood cells, according to a release.
Dr. Matthew Walter will lead the center.
Officials said MDS is hard to detect, with patients suffering from fat igue and shortness of breath.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 12, 2019 Category: Biotechnology Authors: Vince Brennan Source Type: news
Couple Settles With Last Defendant In Benzene Suit On Eve Of Trial
OAKLAND, Calif. - A law firm representing a couple claiming that the man's exposure to benzene-containing products while working as an automobile mechanic caused him to develop myelodysplastic syndrome (MDS) announced July 1 that they had reached a settlement in California state court with the last defendant in the action on the eve of trial, bringing the total settlement amount to $6.3 million (Jimmy H. Thomas, et al. v. AZKO Nobel Coatings Inc., et al., No. RG-17-882514, Calif. Super., Alameda Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 10, 2019 Category: Medical Law Source Type: news
Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)
This is a multicenter, randomized, double-blind, two-arm study to evaluate the safety, tolerability, efficacy and PK of the combination therapy of SCY-078 plus voriconazole compared to those of voriconazole monotherapy in male and female subjects 18 years of age and older with a hematological malignancy (HM) or a myelodysplastic syndrome or aplastic anemia or hematopoietic cell transplantation (HCT) and a probable or proven invasive pulmonary aspergillosis based on EORTCMSG criteria. In addition, all subjects must be positive ( ≥0.5) for serum GMI. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 3, 2019 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Boy, 11, who has a rare blood cancer has been told there is nothing more doctors can do
Oliver Brown, from Devon, was told by doctors he had myelodysplastic syndrome when he was eight years old. At the time, doctors said he was the only boy in the country with the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2019 Category: Consumer Health News Source Type: news
Transfusion Dose Density Affects Myelodysplastic Syndrome Survival
Negative effect of transfusion treatment on PFS occurs at density less than 3 units/16 weeks (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 24, 2019 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news
Transfusion Dose Density Affects Myelodysplastic Syndrome Survival
MONDAY, June 24, 2019 -- Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2019 Category: Pharmaceuticals Source Type: news
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
SUMMIT, N.J.& CAMBRIDGE, Mass.June 04, 2019 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 4, 2019 Category: Drugs & Pharmacology Source Type: news
Lenalidomid Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news
